Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT07222436 · ClinicalTrials.gov registry record

Circulating Tumor DNA in High Risk Localized Prostate Cancer

A clinical trial of Prostate Cancer, sponsored by University of Pittsburgh.

Recruiting
Registry status
24
Enrollment target
1
Study location

NCT07222436 is a study of Prostate Cancer that is actively recruiting participants, run by University of Pittsburgh. The registered enrollment target is 24 participants, below the 608-participant average among 735 other Prostate Cancer trials with a reported enrollment target (96% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT07222436, a study of Prostate Cancer, is actively recruiting participants, sponsored by University of Pittsburgh.

RECRUITING
Registry status
24 participants
Enrollment target
1
Study location

Study Summary

This prospective, non-therapeutic translational biomarker study will collect blood in patients with high risk localized prostate cancer prior to prostatectomy.

Conditions Studied

Study Locations (1)

Pennsylvania

  • UPMC Hillman Cancer Center - Pittsburgh

Trial Details

FieldValue
Enrollment Target 24 participants
Start Date 2025-09-23
Est. Completion 2027-09-30

Sponsor

University of Pittsburgh

1,238 total trials

What the Registry Record Tells You About NCT07222436

The ClinicalTrials.gov registry entry for NCT07222436 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 24 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 608-participant average among 735 other Prostate Cancer trials with a reported enrollment target (96% lower). The listed sponsor is University of Pittsburgh, which has 1,238 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Prostate Cancer appearing as the primary indexed condition, and to 0 interventions.

NCT07222436 reports 1 study location spanning 1 distinct geographic area - top geographies include Pennsylvania.

Frequently Asked Questions

What is clinical trial NCT07222436 about?

NCT07222436 is a clinical study titled "Circulating Tumor DNA in High Risk Localized Prostate Cancer". This prospective, non-therapeutic translational biomarker study will collect blood in patients with high risk localized prostate cancer prior to prostatectomy.

What is the current status of trial NCT07222436?

This trial is currently recruiting. The enrollment target is 24 participants. The study started on 2025-09-23. Estimated completion is 2027-09-30.

What conditions does trial NCT07222436 study?

This clinical trial studies the following conditions: Prostate Cancer.

Who is sponsoring clinical trial NCT07222436?

This trial is sponsored by University of Pittsburgh, which has 1,238 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT07222436 being conducted?

This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Prostate Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.